drugset / Trial / NCT03977220
Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
Investigators assessed the effectiveness of Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
Timeline
- Start
- 2020-01-01
- Primary completion
- 2021-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-paclitaxel | Small molecule | 180 mg/m2 | — |
| Subject | Nab-paclitaxel | Small molecule | 220 mg/m2 | — |
| Subject | Nab-paclitaxel | Small molecule | 260 mg/m2 | — |
| Subject | S-1 | Small molecule | 80 mg | — |
| Subject | S-1 | Small molecule | 120 mg | — |